latest news releases from the newsroom
Generex Biotechnology Corp.
Generex Announces Governmental Approval of its Oral Insulin Spray Product in Lebanon
WORCESTER, Mass., Dec. 23, 2008 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that Lebanon's Ministry of Public Health has approved Generex Oral-lyn, the Company's proprietary oral insulin spray product, for importation, marketing, distribution, and commercial sale in the Republic of Lebanon for the treatment of adults and children with Type-1 or Type-2 diabetes mellitus.
Gulfport Energy Corp
Gulfport Energy Corporation Announces $39.0 Million Gain On the Monetization of Fixed Price Contracts for 2009
OKLAHOMA CITY, Dec. 23, 2008 (GLOBE NEWSWIRE) -- Gulfport Energy Corporation (Nasdaq:GPOR) today announced the monetization of its 2009 fixed price contracts for $39.0 million in cash. Gulfport's fixed price contracts for 2009 provided for the sale of 3,000 barrels of oil per day (BOPD) at a weighted average price of $89.06 per barrel (before transportation costs) for the period January through December 2009. Gulfport retained its remaining fixed price contracts for 2008, which provide for the sale of 3,500 BOPD at a weighted average price of $86.60 per barrel (before transportation costs) through December 31, 2008. Gulfport plans to use proceeds from the sale for general corporate purposes, which may include reducing outstanding borrowings under its revolving credit facility.
MIPS Technologies Announces Modification to Senior Credit Facility
MOUNTAIN VIEW, Calif., Dec. 23, 2008 (GLOBE NEWSWIRE) -- MIPS Technologies, Inc. (Nasdaq:MIPS), a leading provider of industry-standard architectures, processors and analog IP for digital consumer, home networking, wireless, communications and business applications, announced that it has modified its senior credit facility with Silicon Valley Bank to increase the limit it can invest in subsidiaries from $5 million to $13.5 million, subject to meeting certain ongoing financial conditions.